EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis

Malcolm Lim iD, Nicholas L Fletcher iD, Jodi M Saunus iD, Amy E McCart Reed, Haarika Chittoory, Peter T Simpson, Kristofer J Thurecht iD, Sunil R Lakhani

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Malcolm Lim und 7 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Herston, Queensland 4006, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Nanoparticles, Brain Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council, Australian Research Council, University of Queensland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer brain metastases (BM) are associated with a dismal prognosis and very limited treatment options. Standard chemotherapy is challenging in BM patients because the high dosage required for an effective outcome causes unacceptable systemic toxicities, a consequence of poor brain penetration, and a short physiological half-life. Nanomedicines have the potential to circumvent off-target toxicities and factors limiting the efficacy of conventional chemotherapy. The HER3 receptor is commonly expressed in breast cancer BM. Here, we investigate the use of hyperbranched polymers (HBP) functionalized with a HER3 bispecific-antibody fragment for cancer cell-specific targeting and pH-responsive release of doxorubicin (DOX) to selectively deliver and treat BM. We demonstrated that DOX-release from the HBP carrier was controlled, gradual, and greater in endosomal acidic conditions (pH 5.5) relative to physiologic pH (pH 7.4). We showed that the HER3-targeted HBP with DOX payload was HER3-specific and induced cytotoxicity in BT474 breast cancer cells (IC50: 17.6 μg/mL). Therapeutic testing in a BM mouse model showed that HER3-targeted HBP with DOX payload impacted tumor proliferation, reduced tumor size, and prolonged overall survival. HER3-targeted HBP level detected in ex vivo brain samples was 14-fold more than untargeted-HBP. The HBP treatments were well tolerated, with less cardiac and oocyte toxicity compared to free DOX. Taken together, our HER3-targeted HBP nanomedicine has the potential to deliver chemotherapy to BM while reducing chemotherapy-associated toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNanoparticlesBrain NeoplasmsAnimalsMiceHumansFemaleCell Line, TumorDoxorubicinPolymersHydrogen-Ion ConcentrationDrug Delivery SystemsDrug Liberation

Stichwörter der Autor:innen

brain metastasisbreast cancerdrug deliveryhyperbranched polymernanomedicine

Substanzen

DoxorubicinPolymers

Autor:innen und Institutionen

  • UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Herston, Queensland 4006, Australia.
  • Centre for Advanced Imaging, The University of Queensland, Brisbane, St. Lucia, Queensland 4072, Australia.
  • Australian Research Council Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, Brisbane, St. Lucia, Queensland 4072, Australia.
  • Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of Queensland, Brisbane, St. Lucia, Queensland 4072, Australia.
  • Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, St. Lucia, Queensland 4072, Australia.
  • Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, Queensland 4006, Australia.

ORCID-Profile: Malcolm Lim, Nicholas L Fletcher, Jodi M Saunus, Kristofer J Thurecht

Förderung

  • National Health and Medical Research Council
  • Australian Research Council
  • University of Queensland

Zitieren

APA

Lim, M., Fletcher, N. L., Saunus, J. M., McCart Reed, A. E., Chittoory, H., Simpson, P. T., Thurecht, K. J., & Lakhani, S. R. (2023). Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00558

Vancouver

Lim M, Fletcher NL, Saunus JM, McCart Reed AE, Chittoory H, Simpson PT, et al. Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00558

BibTeX
@article{Lim2023,
  author = {Lim, Malcolm and Fletcher, Nicholas L and Saunus, Jodi M and McCart Reed, Amy E and Chittoory, Haarika and Simpson, Peter T and Thurecht, Kristofer J and Lakhani, Sunil R},
  title = {Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00558}
}
Kostenlos starten →